



# The Nano Medicine Revolution

*A science that works  
on the molecular scale  
is set to transform  
personal medicine.*



## NANOTECHNOLOGY FOR MEDICINE

### **MANHATTAN SCIENTIFICS INC.**

OTCQB: MHXT

The Chrysler Building

405 Lexington Avenue, 26th floor

New York • NY • 10174 • Tel: (212) 541.2405

[www.mhtx.com](http://www.mhtx.com)

### **IR & PR CONTACTS**

**Marvin Maslow, Chairman & Founder**

T: (917) 923.3300

E: [marvin@mhtx.com](mailto:marvin@mhtx.com)

**Hawk Associates**

[www.hawkassociates.com](http://www.hawkassociates.com)

### **EXECUTIVE CONTACT**

**Manny Tsoupanarias, CEO**

T: (918) 919.0370

E: [mannyt@mhtx.com](mailto:mannyt@mhtx.com)

### **TECHNICAL CONTACTS**

METALS PROJECT

**Terry C. Lowe**

T: (505) 670.8755

E: [tlowe@mhtx.com](mailto:tlowe@mhtx.com)

CANCER PROJECT

**Robert Proulx**

T: (505) 404.1513

E: [bobproulx@seniorscientific.com](mailto:bobproulx@seniorscientific.com)

Senior Scientific: [www.seniorscientific.com](http://www.seniorscientific.com)



## About Manhattan Scientifics

Manhattan Scientifics Inc. ([www.mhtx.com](http://www.mhtx.com)) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

The Company's business model capitalizes on inventions and technology from which profits could be earned primarily through licensing. MHTX is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market. Manhattan Scientifics assists and acquires early stage technologies and assists entrepreneurial founders and management to stage them to become commercial. Our investment philosophy is defined by our desire to help build innovative companies with exceptional potential. We emphasize novel technologies in the nano-medicine space with the potential to be disruptive and the ability to establish sustainable businesses. We are patient capital with experienced business-building partners who bring the perspective of merchant-bankers not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune 1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (MHTX)

Manhattan Scientifics distinguishes itself from most venture capital firms in that it uses its own, rather than managed capital. Consequently, Manhattan Scientifics' actions are not constrained by preset rules and fund-life-time tables, and the technologist avoids many of the sometimes-adversarial aspects of venture capital relationships. Technologists who are "partnered" with our company also enjoy the diversity of shared success with their brother technologists at Manhattan Scientifics - success at any one of the company's technologies finds its way into the value of our shares, and that success is shared by the entrepreneur whose concept or acceptance in the market place has not yet matured. Manhattan Scientifics brings its expertise with capital, but also with talent including IP counsel, experienced marketers and networkers with global reach.

Such companies allow the new technology to avoid the many pitfalls of the "Do it yourself" approach of startups (most of which fail). Our company earns profit through royalty-bearing licenses as part of the technology transfer process.

## TWO BUSINESSES EXIST WITHIN MANHATTAN SCIENTIFICS (MHTX)

Two nanotechnology businesses exist within Manhattan Scientifics Inc; Both “units” are wholly-owned subsidiaries, both focused on nanotechnology applications in medicine.

### The Ultra Fine Metals Project



The first (Metallicum Inc.) – In 2008, Manhattan Scientifics acquired Metallicum Inc., along with its licensed patented nanostructured metals technology. We also licensed additional related intellectual property from Los Alamos National Laboratory, and filed additional patent applications related to the technology. The technology enables metals with uniform, ultrafine grains. This provides greater strength, lighter weight, and enhanced biocompatibility. It provides significant benefits across a wide range of metal applications – anywhere strength or weight is a concern.

At this time we are exploring and working with partner companies in the fields of titanium dental implants, titanium and magnesium medical devices, high voltage aluminum conductors as well as oil and gas field applications.

On March 25, 2015 the company announced that it had retained Imperial Capital, LLC to explore strategic alternatives for its Metallicum division. We are continuing to develop the base technology for application in other fields of use, and are pursuing industrial partners in those other fields, e.g. aluminum.

### The Nano-Medicine Cancer Project



Manhattan’s second business is called Senior Scientific llc , and is at the crossroads of biotechnology and nanotechnology.

Our novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier

and with higher specificity than is currently possible. We have developed proprietary hardware and software for the highly sensitive detection of nanomagnetic particles that can be linked to antibodies for the detection and treatment of cancer and other human diseases—all without the use of ionizing radiation or large magnetic fields. The technology uses iron oxide nanoparticles and very sensitive magnetic sensors to locate and measure cancer in the body. It can detect cancers 1 million times smaller than current technologies – that’s like the difference between the unaided eye and an electron microscope. It also means detection years earlier – that can be the difference between life and death.

Our novel technologies make possible the earlier detection of cancer in vivo, the ability to analyze biopsies with greater sensitivity and accuracy, the ability to monitor the therapeutic effectiveness of anticancer treatments—both in humans and in animal models—and allow us to detect cancer recurrence with significantly improved sensitivity. Please see: [www.SeniorScientific.com](http://www.SeniorScientific.com)

The technology was developed by Edward R. Flynn, PhD, Senior Scientific's founder and chief scientist, in collaboration with Richard S. Larson, MD, PhD, Executive Vice Chancellor, UNM Health Sciences Center in New Mexico.

Our research facilities are located at the University of New Mexico Science and Technology Park in Albuquerque, New Mexico, where we have longstanding relationships with the University of New Mexico Health Sciences Center, the Los Alamos National Laboratories, and the Center for Integrated Nanotechnology (CINT) at Sandia National Laboratory.

Following a 2-year exclusive license, on June 6, 2011 Manhattan Scientifics (OTC: MHTX) announced its acquisition of Senior Scientific LLC, the body of bio-magnetic detection of cancer technology developed by Edward R. Flynn, Ph.D and supported by the National Institute of Health (NIH).

Dr. Flynn's magnetic field sensors make it possible to identify and image small clusters of cancer cells substantially increasing the sensitivity for finding cancer at a far earlier stage than is currently available, without the use of ionizing radiation or large magnetic fields. The bio-magnetic sensor method is applicable to breast, prostate, ovarian, leukemia, melanoma and other cancers.

Prior to June, 2011, Dr. Flynn's research has been funded (for 8 years) by the NIH; Manhattan Scientifics seamlessly continued funding the research thereafter and intends to identify one or more industrial partners in the Big Pharma group and in the Medical Imaging group, to bring product to the market under royalty-bearing licenses. The process and the challenge is to move from "good science" to "good medicine". The company introduced the breakthrough technology in very early cancer detection and treatment to M.D, Anderson Cancer Center, Houston, in the spring of 2011. It was received with rave reviews.

We are currently building the next generation devices for collaborative use by M.D. Anderson. The technology has been proven in a research prototype instrument funded by the National Institutes of Health.

We are currently developing a commercial instrument for animal measurements. The instrument will be used to generate the preliminary data for the path to clinical use, and will also serve as the basis for product launch into veterinary and research markets. We are scheduled to deliver our cancer diagnostic

device to the MD Anderson Small Animal Imaging Facility early next year. Their work will provide important independent validation of the technology, from a key opinion leader in the market. The most recent advance in this area, fluorescent imaging, was acquired by Perkin Elmer in 2011 for \$600 million. Our cancer diagnostic has many advantages over fluorescent imaging, and we hope to reach even larger valuation.

We are currently building the next generation devices for collaborative use by M.D. Anderson. The technology has been proven in a research prototype instrument funded by the National Institutes of Health. We are currently building the next generation higher performance medical device this year. We expect to have the first commercial instrument operating at our facility Q3 2013. We will use that instrument to further optimize nanoparticles, software tools, and procedures. Results from that instrument will be used to begin marketing to the animal research and veterinary markets, (neither market requires FDA approval) as well as to fuel negotiations with strategic potential partners and prospective acquirers. We intend to place the second instrument in operation at MD Anderson early next year.

We are currently funded for the two devices described above. Results from the first instrument at our lab will better position us to engage a strategic partner to launch the product in the animal markets. Validation at MD Anderson early next year will also position us to engage a strategic partner to begin trials targeting the first human applications.

We are also addressing the Big Pharma and the Medical Imaging corporations where well-capitalized companies will be selected by us as industrial partners to provide capital to accomplish the "heavy lifting" and accelerate bringing product to the market. ***Our goal is to help cure cancer.***




## Company Description & History

In its early years, Manhattan Scientifics' market cap reached \$900 million as its share price approached \$9.00. These lofty heights ended when the NASDAQ bubble broke in year 2000. Today MHTX sells at a fraction of its former levels, yet the company's fundamentals are substantially stronger than at any time during its history. Management is dedicated to restore shareholder value. The MHTX business model, acquiring, patenting, demonstrating and licensing to a major industrial deep pocket partner has been proven with the culmination of the Carpenter relationship in mid-2009. The Company will continue to incubate & commercialize world changing technologies bringing product to market and profit to its shareholders.

The Company's acquisition of Metallicum Inc. in 2008 marked a sea-change away from its previous focus on alternative energy systems. The Company and its industrial partner are exploring commercial applications of a new generation of metals designed to transform the biomedical device industry and the transportation industry, in much the same way as our own Martin Cooper changed the telephone from the original Alexander Graham Bell invention. Similarly, MHTX is forging ahead to transition Edward R. Flynn's very early cancer detection and treatment technology from "bench to bedside" in much the same way as Dr. Jonas Salk ended polio.

Our Science Team includes technology leaders, such as Dr. Martin Cooper, inventor of the cell phone, Dr. Edward R. Flynn, founder of Senior Scientific LLC, Dr. Arthur Kaufman, founder of H-Power, Donald J. Sandstrom, former Division Leader (Ret), Materials Science, LANL, Dr. Terry C. Lowe, founder, Metallicum, Inc. (see our people at [www.mhtx.com](http://www.mhtx.com)) to guide our commercial introduction of disruptive technical innovations.

Below one can see the historical chart and the current 1-year chart of MHTX:





## Management Team & Company Contacts

**Emmanuel Tsoupanarias**, CEO

**Marvin Maslow**, Chairman & Founder

**Leonard Friedman**, Esq., Director

**Frank Georgiou**, Director

**Chris Theoharis**, Director

### SECURITIES COUNSEL

**Stephen M. Fleming-Fleming PLLC**

T: (516) 833.5034

E: [msmf@flemingpllc.com](mailto:msmf@flemingpllc.com)

### PATENT COUNSEL

**V. Gerald Grafe, Esq.**

E: [grafe@grafelawpc.com](mailto:grafe@grafelawpc.com)

### AUDITOR

**AMC Auditing**

T: (702) 522.1645

### TRANSFER AGENT

**Interwest Securities**

T: (801) 272.9294

*The foregoing document contains forward-looking statements which are subject to risk and uncertainty which may be beyond the company's control.*